7 completed, 3 terminated, 1 active not recruiting, 1 not yet recruiting. 12 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 7, Terminated 3, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Tecfidera: new trials by email Literature Review of Tecfidera trials Research Report on Tecfidera
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) Diroximel Fumarate, Dimethyl Fumarate, Fingolimod - Relapsing Forms of Multiple Sclerosis | Phase 3 | Not yet recruiting | Biogen | 185 | 2026-11-16 | 2026-03-19 |
| Dimethyl Fumarate in Adrenomyeloneuropathy Placebo, Dimethyl fumarate - Adrenomyeloneuropathy Without Cerebral Involvement | Phase 2 / Phase 3 | Active not recruiting | Pujol, Aurora, M.D. | 40 | 2024-04-23 | 2026-06-17 |
| Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants Dimethyl Fumarate, Peginterferon Beta-1a, Placebo - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Terminated | Biogen | 11 | 2019-03-19 | 2023-06-15 |
| A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 ALKS 8700, Dimethyl Fumarate - Relapsing Remitting Multiple Sclerosis | Phase 3 | Completed | Biogen | 506 | 2017-03-15 | 2020-07-14 |
| RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. Rituximab, Dimethyl fumarate, Sodium Chloride solution - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Completed | Anders Svenningsson | 200 | 2016-05-01 | 2021-10-12 |
| Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). dimethyl fumarate - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis | Phase 3 | Completed | Biogen | 218 | 2015-08-11 | 2019-06-27 |
| BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis dimethyl fumarate, Placebo - Multiple Sclerosis, Secondary Progressive | Phase 3 | Terminated | Biogen | 58 | 2015-05-01 | 2017-04-26 |
| Tecfidera Slow-Titration Study dimethyl fumarate - Multiple Sclerosis | Phase 3 | Terminated | Biogen | 62 | 2015-04-01 | 2017-05-05 |
| Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) dimethyl fumarate, Interferon β-1a - Relapsing-Remitting Multiple Sclerosis | Phase 3 | Completed | Biogen | 156 | 2014-08-28 | 2026-05-19 |
| Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012 dimethyl fumarate - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Completed | Biogen | 221 | 2014-04-30 | 2017-04-27 |
| An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Placebo, dimethyl fumarate - Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | Phase 3 | Completed | Biogen | 225 | 2013-03-28 | 2018-11-20 |
| BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) dimethyl fumarate, Placebo - Relapsing-Remitting Multiple Sclerosis | Phase 3 | Completed | Biogen | 1736 | 2009-02-03 | 2020-12-31 |
Multiple Sclerosis, Relapsing-Remitting (8) · Multiple Sclerosis (6) · Multiple Sclerosis, Chronic Progressive (1) · Recurrence (1)
Biogen (10) · Anders Svenningsson (1) · Pujol, Aurora, M.D. (1)
United States (7) · Poland (6) · Belgium (5) · Czechia (5) · Italy (4) · Bulgaria (3) · Germany (3) · Spain (3) · Turkey (Türkiye) (3) · Canada (2) · Estonia (2) · France (2) · Hungary (2) · Israel (2) · Kuwait (2)
Anders Svenningsson, MD, PhD (1) · Carlos Casasnovas, MD, PhD (1)
PMID 26932146, PMID 30206820, PMID 30616596, PMID 30918100, PMID 31391949, PMID 31953790, PMID 32426039, PMID 33796143, PMID 35841908, PMID 36169959, PMID 37061656, PMID 38878121, PMID 39570545
2014 (2), 2008 (1), 2015 (1), 2017 (1), 2018 (1), 2023 (1)